Walleye Capital LLC Invests $4.74 Million in Urogen Pharma $URGN

Walleye Capital LLC purchased a new stake in shares of Urogen Pharma (NASDAQ:URGN) in the 2nd quarter, Holdings Channel reports. The fund purchased 346,162 shares of the company’s stock, valued at approximately $4,742,000.

Several other large investors have also recently added to or reduced their stakes in URGN. XTX Topco Ltd increased its holdings in shares of Urogen Pharma by 39.3% during the first quarter. XTX Topco Ltd now owns 25,967 shares of the company’s stock worth $287,000 after buying an additional 7,326 shares in the last quarter. Nuveen LLC bought a new stake in Urogen Pharma during the 1st quarter worth approximately $1,028,000. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma during the 1st quarter valued at $194,000. Oak Ridge Investments LLC increased its holdings in Urogen Pharma by 20.5% during the 1st quarter. Oak Ridge Investments LLC now owns 73,704 shares of the company’s stock valued at $815,000 after purchasing an additional 12,539 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in Urogen Pharma in the 1st quarter valued at $401,000. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Trading Down 5.4%

Shares of NASDAQ:URGN opened at $22.98 on Friday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00. The stock has a market capitalization of $1.08 billion, a P/E ratio of -6.64 and a beta of 1.21. The business has a 50-day moving average price of $21.35 and a two-hundred day moving average price of $17.27.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. The company had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. As a group, equities analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on URGN. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a report on Monday, October 27th. Piper Sandler started coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Insiders Place Their Bets

In related news, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $16.85, for a total transaction of $37,120.55. Following the completion of the sale, the chief financial officer directly owned 2,280 shares of the company’s stock, valued at $38,418. The trade was a 49.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 14,594 shares of company stock valued at $332,813. Company insiders own 4.70% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.